Ocugen Inc Quick Ratio (OCGN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ocugen Inc   (NASDAQ: OCGN)

Ocugen Inc 's Quick Ratio

OCGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.75 below Ocugen Inc average.

Within Biotechnology & Pharmaceuticals industry 118 other companies have achieved higher Quick Ratio than Ocugen Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1307 to 2224.

Explain Quick Ratio?
How much Cash & cash equivalents OCGN´s has?
What are OCGN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OCGN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 639.79 % 22.63 % 6.74 % 29.18 % 0.09 %
Y / Y Cash & cash equivalent Change 270.38 % -15.73 % -68.26 % -15.84 % 72.09 %
Quick Ratio MRQ 0.75 1.54 0.81 1.6 1.5
OCGN's Total Ranking # 2224 # 1307 # 1020 # 1194 # 221
Seq. Current Liabilities Change 542.65 % -10.13 % 13.17 % 13.19 % 6.53 %
Seq. Cash & cash equivalent Change 214.08 % 71.53 % -42.97 % 20.55 % -28.54 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 119
Healthcare Sector # 682
Overall Market # 2224


Quick Ratio Statistics
High Average Low
24.75 5.44 0.11
(Jun 30 2021)   (Jun 30 2019)




Financial Statements
Ocugen Inc 's Current Liabilities $ 133 Millions Visit OCGN's Balance sheet
Ocugen Inc 's Cash & cash equivalent $ 100 Millions Visit OCGN's Balance sheet
Source of OCGN's Sales Visit OCGN's Sales by Geography


Cumulative Ocugen Inc 's Quick Ratio

OCGN's Quick Ratio for the trailling 12 Months

OCGN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 173.02 % 13.7 % 9.68 % 14.88 % 16.03 %
Y / Y Cash & cash equivalent TTM Growth 12.97 % -27.01 % -16.75 % 29.66 % 20.01 %
Quick Ratio TTM 0.93 1.34 1.48 2.03 2.24
Total Ranking TTM # 3968 # 3092 # 1873 # 2420 # 2759
Seq. Current Liabilities TTM Growth 140.18 % 4.88 % 1.89 % 6.37 % 0.02 %
Seq. Cash & cash equivalent TTM Growth 66.4 % -5.13 % -25.62 % -3.78 % 7.51 %

Quick ratio ranking by company, industry and sector >> Back to OCGN Financial Strength Comparisons >> Go to Compare OCGN Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $133.08 millions, cumulative Quick Ratio decreased to 0.93 below the Ocugen Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Ocugen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3092 to 3968.

Explain Quick Ratio?
How much Cash & cash equivalents OCGN´s has?
What are OCGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 142
Healthcare Sector # 896
Within the Market # 3968


trailing twelve months Quick Ratio Statistics
High Average Low
16.23 4.23 0.3
(Dec 31 2021)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Biocardia Inc   2.00 $ 4.117  Millions$ 2.055  Millions
Kymera Therapeutics Inc   1.75 $ 124.477  Millions$ 71.326  Millions
Biocryst Pharmaceuticals Inc   1.69 $ 353.279  Millions$ 208.846  Millions
Coherus Oncology inc   1.69 $ 127.683  Millions$ 75.510  Millions
Bio techne Corp  1.62 $ 264.712  Millions$ 163.700  Millions
Atara Biotherapeutics Inc   1.45 $ 9.900  Millions$ 6.847  Millions
Twist Bioscience Corporation  1.39 $ 166.839  Millions$ 120.255  Millions
Neumora Therapeutics Inc   1.34 $ 116.834  Millions$ 87.478  Millions
Calidi Biotherapeutics Inc   1.33 $ 4.290  Millions$ 3.237  Millions
Passage Bio Inc   1.17 $ 24.155  Millions$ 20.719  Millions
Mink Therapeutics Inc   1.16 $ 8.807  Millions$ 7.569  Millions
Amgen Inc   1.07 $ 27,404.000  Millions$ 25,502.000  Millions
Aligos Therapeutics Inc   1.07 $ 30.381  Millions$ 28.343  Millions
Vaxart Inc   1.05 $ 77.058  Millions$ 73.108  Millions
Iovance Biotherapeutics inc   1.04 $ 110.768  Millions$ 106.848  Millions
Liminatus Pharma Inc   0.99 $ 3.017  Millions$ 3.040  Millions
Elutia Inc   0.95 $ 19.896  Millions$ 21.045  Millions
Jasper Therapeutics Inc   0.93 $ 7.314  Millions$ 7.845  Millions
Protalix Biotherapeutics inc   0.90 $ 28.140  Millions$ 31.391  Millions
Vivosim Labs Inc   0.88 $ 1.670  Millions$ 1.893  Millions
Senti Biosciences Holdings Inc   0.83 $ 13.124  Millions$ 15.765  Millions
Pelthos Therapeutics Inc   0.78 $ 24.776  Millions$ 31.959  Millions
Ocugen Inc   0.75 $ 100.051  Millions$ 133.080  Millions
Sab Biotherapeutics Inc   0.71 $ 8.267  Millions$ 11.705  Millions
Vaxcyte Inc   0.68 $ 183.190  Millions$ 271.277  Millions
Halozyme Therapeutics Inc   0.61 $ 231.081  Millions$ 375.965  Millions
Silexion Therapeutics Corp  0.57 $ 2.258  Millions$ 3.976  Millions
Atlantic Coastal Acquisition Corp Ii  0.52 $ 4.291  Millions$ 8.225  Millions
Surrozen Inc   0.50 $ 102.039  Millions$ 203.292  Millions
Pluri Inc   0.40 $ 13.126  Millions$ 32.719  Millions

Date modified: 2026-09-26T07:08:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.